Pot stock mania has fizzled though there is plenty to be optimistic about in the space. Aurora Cannabis (ACB) investors have weathered the recent onslaught of selling. Mostly owed to a difficult prior quarter earnings report, and also the emergence of a shelf offering that has positive implications for U.S. expansion, but requires significant dilution to reach that objective. Also, pot stock in general were elevated on M&A fueled speculation involving Aphria (APHA) and Tilray (TLRY), which has subsided.
U.S. Expansion versus Canadian and European Markets
However, aside from some hints at U.S. expansion from ACB, it’s becoming very apparent that the U.S. cannabis space has weathered the recent chat room fueled speculation in Canadian Pot stocks better. The key here however is that growth in the U.S. MSO (multi-state operator) space due to recreational weed legislation has limited financial implications for Canadian LPs (licensed producers) with the exception of Aphria perhaps, which managed to get in the U.S. space via a beverage deal.
We think this dynamic could play out more favorably if Aurora Cannabis could either gain market share from other Candian LPs or is able to report stronger growth in European markets. However, ACB has a terrible tendency of missing production goals, and has continued to scale back production from Canadian facilities, and reports also suggest Denmark (nordic) facilities have cut production.
Without having an easy entry into U.S. markets. The situation has to turnaround for its pre-existing cultivation licenses, perhaps more aggressive promotional activity with lower pricing, and better production cost per KG could help improve the narrative. Alternatively, ACB could perform better if they yield higher THC concentrated flower, and could adjust pricing higher for top shelf flower.
Wall Street Expectations Are Extremely Low on the Stock
Most analysts have a negative rating on the stock, however there could be room for surprises for Aurora Cannabis as expectations have already diminished to a point where surprise demand growth, improved sales volumes, pricing per gram, or M&A announcements could drive sentiment back into the stock.
Analyst consensus anticipates that Aurora Cannabis (ACB) will report dil. EPS of -0.21 CAD, and revenue of 71.74M CAD, for Q2’21, which translates to -5% y/y sales growth. In terms of earnings performance, ACB has missed earnings estimates for four consecutive quarters.
Investors probably won’t expect much of an earnings beat, but much of the weakness in terms of dil. EPS metrics ties into sales growth. Assuming ACB can return to sales growth, the dil. EPS metrics should see meaningful improvement, though it’s beyond the scope of this article to anticipate when pricing per gram/volume will normalize across its dispensaries.
Though, it’s broadly anticipated that the weakness in revenue for Q2’21 will be temporary and somewhat of a price recovery per gram, and demand/supply rebalance in the CAD LP space could translate into stronger revenue by Q3’21 where analyst forecast revenue of $77M, which implies 6.9% y/y revenue growth.
Investors may need to wait to find a better exit
Much of the bad has been priced into the stock with ACB trading at $9.14 in the United States. We think pot stocks are due for somewhat of a recovery, but more specifically ACB could perform better over the course of 2021.
We think it’s too early to discount a recovery in the stock, and it’s too late to sell the stock to protect from further losses. At this point, investors will need to wait for better timing to look for an exit. But, news flow, and hype can move quickly through the pot stock space, and any number of positives for the industry could also impact ACB shareholders more favorably down the road as well.
Disclosure: Cho Research was not compensated to publish “Aurora Cannabis Down in the Dumps But Can it Recover?” Though Cho Research does use the research dollars it
generates from other clients of our research service to fund market research
reports such as this. This document is not produced in conjunction with a
security offering and is not an offering to purchase securities. This report
does not consider individual circumstances and does not take into consideration
individual investor preferences. Recipients of this report should consult
professionals around their personal situation, including taxation. Statements
within this report may constitute forward-looking statements, these statements
involve many risk factors and general uncertainties around the business,
industry, and macroeconomic environment. Investors need to be aware of the high
degree of risk in micro capitalization equities, cryptocurrencies, crypto assets.
Independent equity research isn’t regulated by the SECand operates separately from more conventional sell-side equity research. Thepublication of independent equity research is unregulated and rules pertainingto published independent equity research are covered under “freedom of thepress” with legal case precedent taken all the way to theN.Y. Supreme Court to guard against libel based claims or claims of lossrelating to the publication of a report on a company. Any copyright claimrelating to infringement is covered under fair use of copyrighted materials. Sincethe use of material was derived into a separate form of analysis without anysubstantial content derived from any third-party no copyright claim can bepursued under common law. To discuss investment risk or to consider the riskspertaining to any securities it is recommended to consult a registeredfinancial advisor. To understand independent research it’s encouraged to readthis published article on independent equityresearch to become more familiar with industry standard practices and therelative value of independent equity research versus brokerage research andnews media.Cho Research, its subsidiaries, and employees may open along/short equity position at future date from the data of publication of thereport. The price per share and trading volume of subject company and companiesreferenced in this report may fluctuate and Cho Research is not liable forthese inherent market fluctuations. The past performance of this investment isnot indicative of the future performance, no returns are guaranteed, and a lossof capital may occur. Certain transactions, such as those involving futures,options, and other derivatives, can result in substantial risk and are notsuitable for all investors.